The House Energy and Commerce Subcommittee on Health today held a hearing to discuss four bills aimed at making prescription drugs more affordable for Americans. “It is time for Congress to take bold and decisive action to reduce prescription drug prices for all Americans,” said Energy and Commerce Committee Chairman Frank Pallone, D-N.J. Among other bills, the subcommittee discussed the Lower Drug Costs Now Act of 2019 (H.R. 3). Introduced last week by House Democratic leaders, the bill would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs, including allowing the Department of Health and Human Services to negotiate directly with drug manufacturers the price of at least 25 — and up to 250 — brand-name prescription drugs that lack price competition in the market. Witnesses at the hearing were from Baldwin Wallace University, Johns Hopkins Bloomberg School of Public Health and American Enterprise Institute.
 

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Senate Finance Committee Sept. 24 held a markup where it advanced the nomination of Chris Klomp for deputy secretary of the Department of Health and Human…